Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LCTX vs SLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: LCTX 3 – 2 SLN (1 Tie) Matrix Metrics: LCTX 6 – 4 SLN

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin), whereas SLN carries 45.6/100 (HOLD) at $19.81 (N/M Forward P/E, -11905.9% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. SLN 45.6/100 HOLD) and 1.39β · 79% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs SLN
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.81
+0.0% 1D
Market Cap $1.2B
TTM Revenue $456,000
Forward P/E N/M
Beta / 30D Vol 1.77β · 4% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 29.0 Fund 36.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.6% over 20 days), RSI 78
RSI-14: 77.5 · SMA20: $19.78 · SMA50: $15.28

6-Pillar Scorecard Institutional Category Breakdown (LCTX 3 – 2 SLN)

Columns: Metric · LCTX · SLN
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 15.9x N/M
2. Growth & Scale SLN
Revenue Growth (YoY) -61.0% +197.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $456,000
Market Cap $207.4M $1.2B
3. Profitability & Quality LCTX
Gross Margin -95.0% 95.0%
Operating Margin -280.3% -11905.9%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -35.6%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$54M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $3.46 Book/Sh · -35.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 0.0% (<1st %ile) 55.4% (50th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (6) vs SLN (4)
Institutional Metric LCTX SLN Criterion Row Edge
Market Capitalization
Scale
$207.4M $1.2B Larger Scale SLN
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% +197.2% Higher Growth SLN
Operating Margin (TTM)
Profitability
-280.3% -11905.9% Higher Margin LCTX
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -35.6% Higher ROE LCTX
52-Week Range Position
Momentum
0% ($1–$2) 100% ($4–$20) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.39β · 79% Vol 1.77β · 4% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 45.6 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $456,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% 95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 15.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$54M EBITDA ($3.46 Book/Sh · -35.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLN +22.39 pp
LCTX: -21.63% · SLN: +0.76%
3M Horizon SLN +78.24 pp
LCTX: -29.18% · SLN: +49.06%
6M Horizon SLN +260.14 pp
LCTX: -40.62% · SLN: +219.52%
1Y Horizon SLN +262.95 pp
LCTX: -54.86% · SLN: +208.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LCTX vs SLN. Trailing 12-month operating profitability (LCTX -280.3% vs SLN -11905.9%) and valuation multiples (LCTX 30.7x vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LCTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin-95.0%
Op. Margin-280.3%
ROE / Fwd P/E4.3% · 30.7x
SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$456,000
Gross Margin95.0%
Op. Margin-11905.9%
ROE / Fwd P/E-35.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -11905.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs SLN Key Questions & Quantitative Answers

As of Nov 20, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 54.9/100 (HOLD) at $0.77 (30.7x Forward P/E, -280.3% operating margin), whereas SLN carries 45.6/100 (HOLD) at $19.81 (N/M Forward P/E, -11905.9% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. SLN 45.6/100 HOLD) and 1.39β · 79% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SLN leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with SLN at +197.2% YoY revenue growth and +0.0% YoY earnings growth on $456,000 TTM revenue (95.0% gross margin, -11905.9% operating margin). On trailing 12-month operating scale, LCTX generates $11M in USD-normalized revenue versus $456,000 for SLN. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLN.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin), whereas SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus SLN (-35.6% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk). By comparison, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.77β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.